Geratherm Medical AG: Geratherm Medical reports business figures for 2017
Public disclosure of inside information pursuant to Art. 17 MAR, transmitted by DGAP - a service of EQS Group AG
Geratherm Medical reports business figures for 2017
- Sales volume Euro 21 million -1.8 %
- EBITDA Euro 1,768,000 - 52.3 %
- EBITDA (excl. Brazil) Euro 3,114,000 -9.4 %
- EPS 14 cents (2016: 45 cents)
- Proposed dividend 47 cents (2016: 50 cents) per share
Geschwenda, 12 April 2018 - At its meeting today, the supervisory board approved the annual financial statements and consolidated financial statements as per 31 December 2017. The annual financial statements have thus been adopted. The supervisory board accepted the board's proposal for the appropriation of balance sheet profits, namely the payment of a dividend of 47 cents per share.
Although the 51 % stake in Geratherm do Brasil accounts for only 4.3 % of group turnover and 3.6 % of its workforce, the write-downs and losses made by the Brazilian management in the 2017 financial year amounting to Euro 1,563,000 must be consolidated in the consolidated balance sheet of Geratherm as a result of the restructuring which has taken place. This has had an impact on group earnings for the 2017 financial year, which are consequently lower than in the previous year.
The company Geratherm Medical is in a strong position. Its ratio of equity to total balance sheet is 73.8 %, and its liquid assets (including securities held) are valued at Euro 12.8 million (2016: Euro 12 million).
The outlook for business growth in 2018 appears positive. The Warming Systems, Cardio/Stroke and Respiratory business segments are expected to achieve high double-digit growth rates. We have budgeted for the relicensing of the warming systems and the licensing of LMT incubators for China. There will be a 20 % increase in production capacity for gallium thermometers at the site in Geschwenda in 2018.
The detailed annual report will be published on 26 April 2018.
Geratherm Medical AG Firmensitz: Fahrenheitstraße 1, 98716 Geschwenda Registergericht: Amtsgericht Jena, HRB 111272 Vorstand: Dr. Gert Frank Aufsichtsratsvorsitzender: Dipl.-Kfm. Rudolf Bröcker Tel. 036205/98 0; Fax: 036205/98 115 E-Mail: firstname.lastname@example.org
Short company profil: Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MR Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index.Contact: Dr. Gert Frank
12-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Geratherm Medical AG Fahrenheitstraße 1 98716 Geschwenda
Germany Phone: +49 (0)36205 98-0 Fax: +49 (0)36205 98-1 15 E-mail: email@example.com Internet: www.geratherm.com ISIN: DE0005495626 WKN: 549562 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News Service
674061 12-Apr-2018 CET/CEST